Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Study terminated by Sponsor
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| NGM707 Combination Cohort A | Experimental | NGM707 with pembrolizumab in MSS CRC |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| NGM707 plus pembrolizumab | Drug | Drug: NGM707 NGM707 will be administered intravenously (IV) every 3 weeks in a 21 day cycle. Drug: pembrolizumab Pembrolizumab will be administered intravenously (IV) every 3 weeks in a 21 day cycle. |
| Measure | Description | Time Frame |
|---|---|---|
| Objective response rate (ORR) as per RECIST v1.1 | Objective Response Rate is defined as the proportion of patients who achieve a confirmed complete response (CR) or partial response (PR) according to RECIST v1.1 | Baseline up to approximately 24 months |
| Incidence of Adverse Events | Number of patients with adverse events (AEs) according to severity, seriousness, and relationship to study drug An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of patients who experience at least one AE will be presented. | Baseline up to Approximately 24 Months |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Chief Medical Officer | NGM Biopharmaceuticals, Inc | Study Director |
Not provided
Not provided
| ID | Term |
|---|---|
| C582435 | pembrolizumab |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided